Retrospective post-marketing study on the use of bio-similar pegasparagase among acute lymphoblastic leukemia patients in India

Bio-similar PEG-ASP in combination with chemotherapy is safe and well tolerated in Indian patients with ALL. No new safety signal was generated in this analysis. Adverse events reported were similar to those seen with innovator in the global published data.